Agilon Health stock
AGLNYSEAgilon Health, Inc., HealthcareISIN US00857U2069
49Score 49 out of 100, Weak
Price and trend
83 / 100
Price history
+603% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 61% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 15% below its 52-week high. Largest decline in 6 years: 99% (June 2021 to March 2026).
Chart figures for advanced users
- SMA 50$90.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$68.67
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.91
- The lowest closing price of the last twelve months.
- Resistance$129.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Agilon Health, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.85B, is number 31 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.93B (down 2.1% year on year) and a loss of $405.35M.
- For fiscal 2026, analysts expect on average revenue of $5.83B (down 1.8%) and adjusted earnings per share of −$2.33.
Show more
- MEQIRI Score 49 out of 100 (Weak): rank 384 of 702 in Healthcare, median 53.
- Our model puts fair value at $127.48, with the price 13% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 42.5% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 70
- More cash than debtCash $239.76M, financial debt $33.43M.
Weaknesses
- Volatile share priceVolatility 166% a year over the last 12 months.Stability 44
- Loss-makingLoss of $106.04M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$31.08M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 49.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $84.98 and expensive above $254.95 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $109.30, at 7.8% it would be $154.49.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 42.5% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −3%, operating −7%, net −7%. Last 12 months: net −2%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported $1.97 (expected −$1.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.330.0%
- Revenue
- $5.83B0.0%
- Earnings per share
- $1.730.0%
- Revenue
- $6.24B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −8.4%2026 guidance raised: revenue of about $5.8 billion, medical margin of about $485 million, adjusted EBITDA of about $85 million (all at the midpoint).
“Using the midpoint of our guidance ranges for the full year 2026, we now expect revenue of approximately $5.8 billion, medical margin of approximately $485 million, and adjusted EBITDA of approximately $85 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Agilon Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Pediatrix Medical GroupMD $2.45B70
- Addus HomeCareADUS $2.31B70
- Brookdale Senior LivingBKD $2.14B23
- EmeisEMEIS.PA $1.89B41
- AttendoATT.ST $1.84B65
- Healthcare Services GroupHCSG $1.69B70
- Sonida Senior LivingSNDA $1.63B31
- AmbeaAMBEA.ST $1.63B70
ETFs that hold Agilon Health
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.02% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
| Avantis Emerging Markets Equity UCITS ETF USD AccAVEM | 0.00% | 0.35% | €277.45M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.